Literature DB >> 31600750

Rodent Models of Nonalcoholic Fatty Liver Disease.

Fang Zhong1,2,3, Xiaoming Zhou2,3, Jin Xu1,2,3, Ling Gao4,5,6.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a continuous diseases spectrum associated with obesity, type 2 diabetes, insulin resistance, and hyperlipidemia. Simple hepatic steatosis may progress to nonalcoholic steatohepatitis (NASH), even fibrosis and cirrhosis, and finally hepatocellular carcinoma. In recent years, NAFLD has become a public health concern with increasing prevalence. However, the mechanisms underlying the pathogenesis remain incompletely understood, and few effective therapeutic approaches are available. Summary and Key Messages: A myriad of different rodent models has been developed to elucidate pathophysiology of NAFLD/NASH and guide therapeutic strategy. To date, no single rodent model can display the whole disease spectrum and metabolic features associated with human NASH, but can imitate particular characteristics. In this paper, we review the most commonly used dietary, genetic, and chemical rodent models for NAFLD referring to their advantages and disadvantages. Also, we illustrate the status of latest treatment strategy using various NAFLD rodent models. We hope to provide critical guidance for researchers to select appropriate animal models.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Animal model; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Rodent model

Mesh:

Substances:

Year:  2019        PMID: 31600750     DOI: 10.1159/000501851

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  25 in total

1.  Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist.

Authors:  Rayane Miranda Pontes-da-Silva; Thatiany de Souza Marinho; Luiz Eduardo de Macedo Cardoso; Carlos Alberto Mandarim-de-Lacerda; Marcia Barbosa Aguila
Journal:  Int J Obes (Lond)       Date:  2021-08-31       Impact factor: 5.095

2.  High fat high sucrose diet-induced dyslipidemia in guinea pigs.

Authors:  Cynthia R Muller; Alexander T Williams; Allyn M Eaker; Fernando Dos Santos; Andre F Palmer; Pedro Cabrales
Journal:  J Appl Physiol (1985)       Date:  2021-03-11

3.  Impact of liver-specific GLUT8 silencing on fructose-induced inflammation and omega oxidation.

Authors:  Marta G Novelle; Susana Belén Bravo; Maxime Deshons; Cristina Iglesias; María García-Vence; Rebecca Annells; Natália da Silva Lima; Rubén Nogueiras; Manuel Alejandro Fernández-Rojo; Carlos Diéguez; Amparo Romero-Picó
Journal:  iScience       Date:  2021-01-19

4.  A novel chicken model of fatty liver disease induced by high cholesterol and low choline diets.

Authors:  Chiao-Wei Lin; Ting-Wei Huang; Yu-Ju Peng; Yuan-Yu Lin; Harry John Mersmann; Shih-Torng Ding
Journal:  Poult Sci       Date:  2020-11-30       Impact factor: 3.352

Review 5.  Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research.

Authors:  Clarissa Berardo; Laura Giuseppina Di Pasqua; Marta Cagna; Plinio Richelmi; Mariapia Vairetti; Andrea Ferrigno
Journal:  Int J Mol Sci       Date:  2020-12-17       Impact factor: 5.923

6.  The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model.

Authors:  Linfu Liu; Chuang Liu; Manyu Zhao; Qianru Zhang; Ying Lu; Ping Liu; Hua Yang; Jinliang Yang; Xiaoxin Chen; Yuqin Yao
Journal:  PLoS One       Date:  2020-12-16       Impact factor: 3.240

7.  Attenuating Effects of Dieckol on High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease by Decreasing the NLRP3 Inflammasome and Pyroptosis.

Authors:  Seyeon Oh; Myeongjoo Son; Kyung-A Byun; Ji Tae Jang; Chang Hu Choi; Kuk Hui Son; Kyunghee Byun
Journal:  Mar Drugs       Date:  2021-05-30       Impact factor: 5.118

8.  Herbal formulation MIT ameliorates high-fat diet-induced non-alcoholic fatty liver disease.

Authors:  Sang-Hyun Ahn; Eun-Sun Yang; Hey-Rin Cho; Syng-Ook Lee; Ki-Tae Ha; Kibong Kim
Journal:  Integr Med Res       Date:  2020-05-14

9.  Osr1 regulates hepatic inflammation and cell survival in the progression of non-alcoholic fatty liver disease.

Authors:  Yi Zhou; Zhimin Liu; Ernest C Lynch; Leya He; Henghui Cheng; Lin Liu; Zhen Li; Jiangyuan Li; Lauren Lawless; Ke K Zhang; Linglin Xie
Journal:  Lab Invest       Date:  2020-10-01       Impact factor: 5.662

10.  TGR5 Regulates Macrophage Inflammation in Nonalcoholic Steatohepatitis by Modulating NLRP3 Inflammasome Activation.

Authors:  Yong Shi; Wantong Su; Lei Zhang; Chengyu Shi; Jinren Zhou; Peng Wang; Hao Wang; Xiaoli Shi; Song Wei; Qi Wang; Johan Auwerx; Kristina Schoonjans; Yue Yu; Rui Pan; Haoming Zhou; Ling Lu
Journal:  Front Immunol       Date:  2021-02-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.